Celeste brings decades of global experience overseeing all phases of clinical trials and drug development across multiple therapeutic areas to Senda Biosciences. She is an accomplished leader who has driven the advancement of programs from clinical proof of concept through regulatory approval and has significant success in building high performing teams with broad organizational impact.
Celeste began her career in academia and subsequently worked at Sanofi for 18 years where she held clinical operations and program management roles of increasing responsibility. More recently, Celeste held positions at mid- and small- sized Biotechnology companies such Sarepta, where she was instrumental in obtaining FDA approval for Exondys 51® (the first drug for Duchenne Muscular Dystrophy), and X4 Pharmaceuticals, where she held the positions of VP of Clinical Operations and Project Leader for their lead program.
Celeste received her B.S. degree in Biology at Shippensburg University and her Master’s in Psychology at Immaculata University. She has served as Adjunct Instructor for the graduate-level capstone program at Massachusetts College of Pharmacy and Health Sciences (MCPHS) and is an active member of her community.